AKBA — Akebia Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1517022 ·
Last close
$0.40
Market Cap
$111.18M
52W High
$1.75
52W Low
$0.36
ADV30
8,592,878
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 36,903,000 30,541,000 -10,119,000 -14,354,000 342,127,000 159,254,000 321,758,000
Jun 2026 49,128,000 38,704,000 -4,381,000 -8,908,000 349,658,000 155,548,000 324,640,000
Mar 2026 53,544,000 41,254,000 -4,696,000 -9,054,000 362,520,000 162,644,000 335,145,000
Dec 2025 57,622,000 45,087,000 -8,553,000 -12,244,000 376,565,000 184,844,000 343,955,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$15,779,000
Investing CF
$-14,624,000
Financing CF
$-9,136,000
CapEx
$-14,624,000
Dividends Paid
—
Buybacks
$-63,000
EPS Diluted TTM
$-0.16
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,716,021,000
Inventory
$18,702,000
Receivables
$36,440,000
ST Investments
—
EBIT TTM
$-27,449,000
Pretax Income TTM
$-43,180,000
Interest Exp TTM
$15,731,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$197,196,992
EBITDA
$-18,757,000
Free Cash Flow
$6,833,625
Enterprise Value
$158,941,520
Total Cash
$159,254,000
Total Debt
$206,768,992
Shares Out
277,663,875
Trailing EPS
$-0.17
Book Value
$0.07
ROE
-143.8%
ROA
-3.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 236,196,000 23,499,000 -5,345,000 376,565,000 343,955,000 32,610,000 67,992,000
Dec 2024 160,180,000 -50,414,000 -69,410,000 220,670,000 269,855,000 -49,185,000 -40,659,000
Dec 2023 194,623,000 -46,075,000 -51,925,000 241,703,000 272,287,000 -30,584,000 -23,384,000
Dec 2022 292,484,000 -64,846,000 -94,226,000 356,054,000 350,824,000 5,230,000 -73,154,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$219,060,000
NetIncome TTM
$-29,666,000
OpCashFlow TTM
—
Assets (Latest)
$349,658,000
Forward EPS
$-0.36

Max Pain — expiry 2027-01-15

max pain strike: $0.50 · spot: $0.41 · call oi: 1,113 · put oi: 335
Expected Move to 2027-01-15: ±$0.47 (116.14%) — implied range $-0.07 – $0.88 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
FHTX Foghorn Therapeutics Inc. $109.73M $1.83 —
SCNX Scienture Holdings, Inc. $113.34M $2.76 —
UPB Upstream Bio, Inc. $115.10M $2.10 —
SPRB SPRUCE BIOSCIENCES, INC. $116.37M $40.49 —
NRXP NRX Pharmaceuticals, Inc. $106.07M $2.45 —

News headlines (Yahoo Finance, 1h cache)

Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
2026-11-17 21:05 · Yahoo
Akebia (AKBA) Q3 2026 Earnings Call Transcript
2026-11-06 18:01 · Yahoo
Akebia Therapeutics Inc (AKBA) (Q3 2026) Earnings Call Highlights: Vafseo Demand Outpaces ...
2026-11-06 07:13 · Yahoo
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
2026-11-05 16:15 · Yahoo
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Akebia Therapeutics: Q3 Earnings Snapshot
2026-11-05 12:24 · Yahoo
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-05 12:10 · Yahoo
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin
2026-11-05 12:00 · Yahoo
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-10-29 12:00 · Yahoo
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephro
2026-10-26 13:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.